The TRAMP-C1 and Myc-CaP murine prostate cancer models were carefully selected to reflect clinically relevant subtypes of advanced prostate cancer, ensuring that findings from this study can be meaningfully translated into patient care. This evidence concerns the gene MYC and Familial prostate cancer.